| Literature DB >> 32513626 |
Andrea Postigo1, Ana González-Mansilla1, Javier Bermejo1, Jaime Elízaga1, Francisco Fernández-Avilés1, Manuel Martínez-Sellés2.
Abstract
Entities:
Mesh:
Year: 2020 PMID: 32513626 PMCID: PMC7245220 DOI: 10.1016/j.rec.2020.04.018
Source DB: PubMed Journal: Rev Esp Cardiol (Engl Ed) ISSN: 1885-5857
Reasons for visit, history of heart disease, and actions taken in 278 patients
| Type | Age, y | Women | Reason for visit/heart disease | Tests performed | Treatment | Follow-up, mo | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| New, in-person | 76 (27) | 59 ± 19 | 38 (61.3) | Chest pain | 12 (19.3) | Electrocardiogram | 53 (85.5) | Discharge | 35 (56.2) | 8 ± 10 |
| Symptoms of HF | 6 (9.7) | TTE | 40 (64.5) | Treatment changes | 8 (12.9) | |||||
| Palpitations | 11 (17.7) | Stress test | 5 (6.5) | Additional tests | 21 (33.8) | |||||
| Dizziness/syncope | 3 (4.8) | |||||||||
| Murmur | 3 (4.8) | |||||||||
| ECG abnormalities | 9 (14.5) | |||||||||
| Family screening | 9 (14.5) | |||||||||
| Other | 9 (14.5) | |||||||||
| Follow-up visits, telemedicine visit | 202 (73) | 66 ± 17 | 78 (41.1) | Ischemic heart disease | 50 (26.3) | — | Discharge | 38 (20.0) | 9 ± 5 | |
| Valvular heart disease | 35 (18.4) | Treatment changes | 42 (22.1) | |||||||
| HF | 23 (12.1) | Additional tests | 106 (55.8) | |||||||
| Cardiomyopathies | 17 (8.9) | |||||||||
| Arrhythmias | 38 (20) | |||||||||
| Congenital heart disease | 9 (4.7) | |||||||||
| Pulmonary hypertension | 5 (2.6%) | |||||||||
| Other | 13 (6.8) | |||||||||
ECG, electrocardiography; HF, heart failure; TTE, transthoracic echocardiography.
The values are expressed as No. (%) or mean ± standard deviation.
Figure 1Organizational chart for Outpatient Cardiology Department visits during the SARS-CoV-2 pandemic.